Prince Joachim and Princess Marie of Denmark have opened up for the first time about his life-threatening stroke last summer.
Joachim, 51, was on holiday with his family in France when he suddenly suffered a blood clot and had to be rushed to Toulouse University Hospital to receive emergency surgery.
Joachim, who lives in Paris with Marie, 45, spent the rest of the summer recuperating at the Danish royals summer residence, Chateau de Cayx in Cahors in southern France before returning to Paris, to start a new job as a Defense Attaché at the Danish Embassy in September.
Eight months on, the Danish Prince and his wife opened up about the ordeal in an interview with Hjernesagen s member magazine, where Marie admitted the stroke could have changed their lives.
Princess Marie and Prince Joachim of Denmark open up about his stroke
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Study: Lorlatinib and Crizotinib Have Comparable Time to Treatment Deterioration in Patients With ALK-Positive NSCLC
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
E-Mail
(Singapore January 31, 2021 2:40 p.m. SPT 1:40 a.m. EST) Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer s 2020 World Conference on Lung Cancer Singapore.
Lorlatinib, a third-generation ALK inhibitor, significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC.
Dr. Julien Mazieres, Toulouse University Hospital, in Toulouse, France presented the detailed results of patient reported outcomes (PROs) from his same study.